Genentech Adds to Avastin's Arsenal
623932
The lead drug gains another use -- just not the one investors expected.
655606
Cancer patients treated with Genentech  Inc.'s colon cancer drug Avastin along with the chemotherapy  regimen FOLFOX4 lived longer than patients treated with the  chemotherapy alone in a late-stage clinical trial, the biotech  company said on Monday.
262304
Shares of Genentech Inc. DNA.N, OSI  Pharmaceuticals Inc. OSIP.O and ImClone Systems Inc. IMCL.O  surged before the bell on Friday after rival AstraZeneca Plc  AZN.L said its lung cancer drug Iressa failed to show  survival benefits in a major clinical study.
578530
Biotechnology company Genentech Inc   said on Monday its fourth-quarter profit rose 6.4  percent, but sales of its blockbuster cancer drug and others  fell short of investor expectations, sending the company's  shares lower.
44693
Celera Genomics Group of Rockville announced an agreement Tuesday to provide potential targets for cancer drugs to biotech giant Genentech Inc. -The Washington Post
139125
Genentech Inc. DNA.N on Wednesday  posted a 50 percent rise in quarterly profit and raised its  full-year earnings forecast on strong sales of its new colon  cancer drug, sending its shares higher in after-hours trading.
608900
Biotechnology company Genentech Inc   said on Monday its fourth-quarter profit rose 6.4  percent, but sales of several drugs, including blockbuster  cancer drug Avastin, fell short of investor expectations,  sending the company's shares lower.
249246
Genentech and Biogen Idec's drug shows positive results against multiple sclerosis.
177682
Genentech appears to have resolved a dispute with ophthalmologists that will allow its drug Avastin to continue to be used to treat eye diseases, boths sides said.
719738
Genentech Inc. on Monday said its colon cancer drug Avastin extended the life of patients when used in combination with a chemotherapy regimen called FOLFOX4 more than the chemotherapy alone in a late stage clinical trial.
688355
Genentech Inc.  said on Wednesday that second-quarter profit rose 41 percent, fueled by growth from cancer drugs Rituxan and Avastin.
421575
Genentech and OSI Pharmaceuticals won federal approval yesterday to sell Tarceva, a pill to treat lung cancer. The approval by the Food and Drug Administration came well before the agency&#39;s
108225
Genentech appears to have resolved a dispute with ophthalmologists over use of the companyâs drug Avastin to treat eye diseases.
603826
Biotechnology companies Genentech Inc. and OSI Pharmaceuticals Inc. on Thursday said U.S. regulators have approved their drug Tarceva as a treatment for the most common form of lung cancer.
297310
U.S. regulators have approved wider use of Genentech Inc. and Biogen Idec Inc.'s drug Rituxan for patients with a type of lymphoma, the companies announced on Friday.
261903
Genentech Inc.  on Wednesday said third-quarter earnings rose 50 percent, spurred by growth in new colon cancer treatment Avastin and strong sales of its older drugs, and raised its full-year profit forecast.
375525
Genentech Inc. has added warnings about a rare brain condition called reversible posterior leukoencephalopathy syndrome, or RPLS, in patients using its cancer drug Avastin, the Food and Drug Administration said.